Henry Schein (NASDAQ:HSIC) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Henry Schein (NASDAQ:HSIC) released its quarterly earnings results on Tuesday. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03, FiscalAI reports. The business had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.10 earnings per share. Henry Schein updated its FY 2026 guidance to 5.290-5.390 EPS.

Here are the key takeaways from Henry Schein’s conference call:

• Strong second-quarter performance: Global sales rose 6.7% to $3.5 billion, while non-GAAP operating income increased 10.5% and non-GAAP EPS grew 15.5% to $1.27, supported by 25 basis points of operating-margin expansion.
• Henry Schein raised its 2026 outlook, now expecting sales growth of 4.5%–5.5% and non-GAAP EPS of $5.29–$5.39, or 6%–8% growth. Management cited sustained sales momentum and stronger underlying performance, though the outlook excludes further remeasurement gains.
• The company remains on track for more than $200 million in operating-income improvements from its value-creation program, including a $125 million run-rate by year-end 2026; outsourcing, procurement consolidation, and pricing initiatives are beginning to contribute.
• Henry Schein One continued to post strong growth, with nearly 13,000 Dentrix Ascend and Dentally cloud customers and approximately 90% recurring revenue. AI-enabled clinical and practice-management tools are driving upgrades to higher-value packages and could increase customer retention and share of wallet.
• Growth was uneven across markets: U.S. dental merchandise and international businesses gained momentum, while U.S. dental equipment faced difficult comparisons and medical sales remained pressured by lower point-of-care diagnostic demand. Management expects U.S. equipment growth in the second half, but acknowledged that higher-margin specialty and technology mix benefits may be partly offset by equipment sales.

Henry Schein Price Performance

Shares of HSIC traded up $2.87 during midday trading on Tuesday, reaching $89.38. The stock had a trading volume of 699,398 shares, compared to its average volume of 1,384,093. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75. The company has a market capitalization of $10.18 billion, a P/E ratio of 26.98, a P/E/G ratio of 1.65 and a beta of 0.80. The firm’s 50 day moving average price is $82.44 and its 200-day moving average price is $78.38. Henry Schein has a 52 week low of $61.94 and a 52 week high of $92.18.

Insiders Place Their Bets

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by corporate insiders.

Institutional Trading of Henry Schein

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new position in Henry Schein in the second quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the 2nd quarter valued at $27,000. Federated Hermes Inc. acquired a new stake in shares of Henry Schein during the 4th quarter valued at $32,000. Los Angeles Capital Management LLC bought a new stake in shares of Henry Schein during the 4th quarter worth $37,000. Finally, Palisade Asset Management LLC bought a new stake in shares of Henry Schein during the 3rd quarter worth $100,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HSIC has been the topic of several analyst reports. BMO Capital Markets began coverage on shares of Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target on the stock. UBS Group reissued a “neutral” rating and issued a $89.00 price objective (up from $85.00) on shares of Henry Schein in a report on Tuesday, July 28th. Mizuho lowered their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Robert W. Baird set a $97.00 price target on Henry Schein in a research report on Wednesday, May 6th. Finally, Citigroup started coverage on Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $89.36.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.